Newtown PA – November 25, 2014 – Helius Medical Technologies (CSE: HSM) (“HMT”, “Helius” or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, has retained The Trout Group LLC, a leading international New York-headquartered life sciences investor relations and strategic advisory firm. The Trout Group will work with Helius to increase the Company’s exposure to the capital markets by developing relationships with portfolio managers, investment bankers, and industry analysts in the United States and Europe.
“We believe our PoNS™ device has the potential to dramatically improve the lives of patients suffering from a number of debilitating neurological diseases. As we progress through the clinical trial process we want to maximize our exposure to the most sophisticated and critical scientific and investor pool possible. With their extensive history in life sciences, we believe The Trout Group is best positioned to facilitate this process,” stated Philippe Deschamps, Helius’ Chief Executive Officer.
“The recent advances in neuroscience and brain imaging create a neurostimulation space that should continue to trigger the interest of the financial community,” said Todd James, Vice President at The Trout Group. “We are intrigued by the early, yet compelling, evidence that has been generated on the PoNS™ device and believe their lead indication, traumatic brain injury, represents a large, unmet medical need. Successful development of PoNS™ for this indication could have a significant impact on patients’ quality of life, specifically for our military veterans. The Trout Group looks forward to working with Helius Medical Technologies to advance this novel approach to brain rehabilitation therapy.”
In consideration of the services to be provided by The Trout Group, the Company has agreed to pay a quarterly retainer.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology holding company focused on neurological wellness. HMT’s mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
About The Trout Group
The Trout Group is the leading global investor relations and strategic advisory firm servicing the life sciences industry. Since 1996, the firm has been providing companies with expert counsel and access to the institutional investment community.
With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. The firm’s global reach extends through a network of offices in New York, Boston, San Francisco, London, Sydney and Shanghai with contacts in all major financial centers, helping clients to connect with the right investors.
- Corporate Contact: Phil Deschamps, 614-596-2597 or firstname.lastname@example.org
- US Investor Relations Contact: Todd James, 646-378-2926 or email@example.com
- Canadian Investor Relations Contact: 778-588-7144 or firstname.lastname@example.org
- Media Contact: Becky Kern, 914-772-2310 or email@example.com
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Safe Harbor Statement
This news release contains forward-looking statements relating to the completion of the listing of the Company’s shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.